64473-35-4

Usage

Uses

Used in Chemical Synthesis:
1-(3-bromopropyl)-4-chlorobenzene is used as a precursor or intermediate for the synthesis of more complex organic compounds. Its unique structure with both bromine and chlorine atoms allows it to be a valuable building block in the production of various chemical products.
Used in Pharmaceutical Industry:
1-(3-bromopropyl)-4-chlorobenzene is used as a chemical intermediate in the development of pharmaceuticals. Its reactivity and structural features make it a useful component in the synthesis of new drug molecules, potentially leading to the discovery of novel therapeutic agents.
Used in Pesticide Production:
1-(3-bromopropyl)-4-chlorobenzene is used as a starting material in the production of certain pesticides. Its halogenated nature contributes to the effectiveness of these agricultural chemicals, helping to control pests and protect crops.
Used in Dye Manufacturing:
1-(3-bromopropyl)-4-chlorobenzene is used as an intermediate in the synthesis of dyes. Its chemical properties enable the creation of a wide range of colors and hues, making it an essential component in the dye industry.
Safety Considerations:
Due to its reactive nature and volatility, 1-(3-bromopropyl)-4-chlorobenzene poses potential hazards, including skin, eye, and respiratory irritation. Proper handling and safety measures are essential when working with 1-(3-bromopropyl)-4-chlorobenzene to minimize risks and ensure the well-being of those involved in its production and use.

Upstream product

• 6282-88-8 3-(p-chlorophenyl)propanol 
• 1798-84-1 1-chloro-4-cyclopropylbenzene 
• 106-39-8 bromochlorobenzene 
• 109-64-8 1,3-dibromo-propane 
• 6529-53-9 1-(2-bromoethyl)-4-chlorobenzene 
• 37556-13-1 diethyl (4-chlorobenzyl)malonate 
• 558-13-4 carbon tetrabromide 
• 2019-34-3 3-(4-chlorophenyl)propanoic acid 
• 104-88-1 4-chlorobenzaldehyde 
• 20754-21-6 methyl 3-(4-chlorophenyl)propenoate 
• 7116-36-1 ethyl 3-(4-chlorophenyl)propanoate 
• 24393-52-0 ethyl (E)-3-(4-chlorophenyl)prop-2-enoate 
• 1615-02-7 3-(4-chlorophenyl)prop-2-enoic acid 

Downstream Products

• 86373-85-5 3-[3-(4-Chloro-phenyl)-propylamino]-benzoic acid ethyl ester 
• 86373-89-9 2-{4-[3-(4-Chloro-phenyl)-propylamino]-phenyl}-propionic acid ethyl ester 
• 86373-87-7 {4-[3-(4-Chloro-phenyl)-propylamino]-phenyl}-acetic acid ethyl ester 
• 86373-91-3 4-[3-(4-Chloro-phenyl)-propylamino]-phthalic acid diethyl ester 
• 112887-55-5 2-acetylaminomethyl-4-[3-(4-chlorophenoxy)propyl]morpholine 
• 112298-30-3 5-(p-chlorophenyl)-1,1,1-trifluoropentan-2-one 
• 467223-70-7 (1''S,1'''R,3''S,6''R)-(2''E)-2-[2'-[3''-(1'''-carboxy-4'''-p-chlorophenylbutyl)-6''-methyl-2''-[(trimethylsilyl)methylene]cyclohexyl]ethyl]-2,5,5-trimethyl-1,3-dioxane 
• 175219-67-7 3-(4-chlorophenyl)propane-1-thiol 
• 181884-83-3 octahydro-3,6-dimethyl-9-[3-(p-chlorophenyl)propyl]-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10(3H)-one 
• 86373-86-6 3-[3-(4-Chloro-phenyl)-propylamino]-benzoic acid 
• 86373-88-8 {4-[3-(4-Chloro-phenyl)-propylamino]-phenyl}-acetic acid 
• 86373-90-2 2-{4-[3-(4-Chloro-phenyl)-propylamino]-phenyl}-propionic acid 
• 86373-92-4 2-[3-(4-Chloro-phenyl)-propylamino]-terephthalic acid 
• 112887-45-3 2-aminomethyl-4-[3-(4-chlorophenoxy)propyl]morpholine 

Relevant academic research and scientific papers

B(C6F5)3-Catalyzed Diastereoselective Formal (4 + 1)-Cycloaddition of Vinylcyclopropanes and Et2SiH2

A formal (4 + 1)-cycloaddition of vinylcyclopropanes and Et2SiH2 to afford 3,4-disubstituted silolanes is reported. The reaction sequence commences with the known B(C6F5)3-catalyzed alkene hydrosilylation with dihydrosilanes. Cleavage of the remaining Si-H bond in the hydrosilylation product assisted by B(C6F5)3 leads to formation of a cyclopropane-stabilized silylium ion. The activated cyclopropane ring is then opened by the in situ-generated borohydride accompanied by ring closure to the silolane. The diastereoselectivity is rationalized by a mechanistic model.

Boron tribromide as a reagent for anti-Markovnikov addition of HBr to cyclopropanes

Although radical formation from a trialkylborane is well documented, the analogous reaction mode is unknown for trihaloboranes. We have discovered the generation of bromine radicals from boron tribromide and simple proton sources, such as water ortert-butanol, under open-flask conditions. Cyclopropanes bearing a variety of substituents were hydro- and deuterio-brominated to furnish anti-Markovnikov products in a highly regioselective fashion. NMR mechanistic studies and DFT calculations point to a radical pathway instead of the conventional ionic mechanism expected for BBr3

Chemical modification-mediated optimisation of bronchodilatory activity of mepenzolate, a muscarinic receptor antagonist with anti-inflammatory activity

The treatment for patients with chronic obstructive pulmonary disease (COPD) usually involves a combination of anti-inflammatory and bronchodilatory drugs. We recently found that mepenzolate bromide (1) and its derivative, 3-(2-hydroxy-2, 2-diphenylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide (5), have both anti-inflammatory and bronchodilatory activities. We chemically modified 5 with a view to obtain derivatives with both anti-inflammatory and longer-lasting bronchodilatory activities. Among the synthesized compounds, (R)-(–)-12 ((R)-3-(2-hydroxy-2,2-diphenylacetoxy)-1-(3-phenylpropyl)-1-azoniabicyclo[2.2.2]octane bromide) showed the highest affinity in vitro for the human muscarinic M3 receptor (hM3R). Compared to 1 and 5, (R)-(–)-12 exhibited longer-lasting bronchodilatory activity and equivalent anti-inflammatory effect in mice. The long-term intratracheal administration of (R)-(–)-12 suppressed porcine pancreatic elastase-induced pulmonary emphysema in mice, whereas the same procedure with a long-acting muscarinic antagonist used clinically (tiotropium bromide) did not. These results suggest that (R)-(–)-12 might be therapeutically beneficial for use with COPD patients given the improved effects seen against both inflammatory pulmonary emphysema and airflow limitation in this animal model.

Anodic benzylic C(sp3)-H amination: Unified access to pyrrolidines and piperidines

An electrochemical aliphatic C-H amination strategy was developed to access the important heterocyclic motifs of pyrrolidines and piperidines within a uniform reaction protocol. The mechanism of this unprecedented C-H amination strategy involves anodic C-H activation to generate a benzylic cation, which is efficiently trapped by a nitrogen nucleophile. The applicability of the process is demonstrated for 40 examples comprising both 5- and 6-membered ring formations.

SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF

This invention provides compounds of formula (I): wherein R1a, R1b, Ra, R2a, R2b, R1, and X have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.

FLAVIN DERIVATIVES

The present invention relates novel flavin derivatives, their use and compositions for use as riboswitch ligands and/or anti-infectives.

ANTIFUNGAL 1, 2, 4-TRIAZOLYL DERIVATIVES

The present invention relates to novel triazole compounds of the formulae (I), (Il) and (IV) as defined below, to agricultural and pharmaceutical compositions containing them and to their use as fungicides, antimycotic, anticancer and antiviral agents.

AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF

Provided is a novel amine compound represented by the following formula (I) having a superior peripheral blood lymphocyte decreasing action and superior in the immunosuppressive action, rejection suppressive action and the like, which shows decreased side effects of, for example, bradycardia and the like, or a pharmaceutically acceptable acid addition salt thereof, or a hydrate thereof, or a solvate thereof. wherein each symbol is as defined in the specification.

Synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a range of 4-substituted phenyl alkyl imidazole-based inhibitors of the enzyme complex 17α-hydroxylase/17,20-lyase (P45017α)

We report the preliminary results of the synthesis, biochemical evaluation and rationalisation of the inhibitory activity of a number of phenyl alkyl imidazole-based compounds as inhibitors of the two components of 17α-hydroxylase/17,20-lyase (P45017α), that is, 17α-hydroxylase (17α-OHase) and 17,20-lyase (lyase). The results show that N-3-(4-bromophenyl) propyl imidazole (12) (IC50 = 2.95 μM against 17α-OHase and IC50 = 0.33 μM against lyase) is the most potent compound within the current study, in comparison to ketoconazole (KTZ) (IC50 = 3.76 μM against 17α-OHase and IC50 = 1.66 μM against lyase). Modelling of these compounds suggests that the length of the alkyl chain enhances the interaction between the inhibitor and the area of the active site corresponding to the C(3) area of the steroid backbone, thereby increasing potency.

Synthesis of N-glyoxyl prolyl and pipecolyl amides and thioesters and evaluation of their in vitro and in vivo nerve regenerative effects

The recent discovery that small molecule ligands for the peptidyl-prolyl isomerase (PPIase) FKBP12 possess powerful neuroprotective and neuroregenerative properties in vitro and in vivo suggests therapeutic utility for such compounds in neurodegenerative disease. The neurotrophic effects of these compounds are independent of the immunosuppressive pathways by which drugs such as FK506 and rapamycin operate. Previous work by ourselves and other groups exploring the structure-activity relationships (SAR) of small molecules that mimic only the FKBP binding domain portion of FK506 has focused on esters of proline and pipecolic acid. We have explored amide and thioester analogues of these earlier structures and found that they too are extremely potent in promoting recovery of lesioned dopaminergic pathways in a mouse model of Parkinson's disease. Several compounds were shown to be highly effective upon oral administration after lesioning of the dopaminergic pathway, providing further evidence of the potential clinical utility of a variety of structural classes of FKBP12 ligands.